SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

The sales figure stood at Rs. 7289.40 millions for the December 2022 quarter. The mentioned figure indicates a growth of about 36.69% as compared to Rs. 5332.70 millions during the year-ago period.Net Profit recorded in the quarter ended December 2022 rise to 35.71% to Rs. 1012.10  millions  compared to R. 745.80 millions in corresponding previous quarter.The company reported a good operating profit of 1726.00 millions compared to 1186.60 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202212 202112 % Var 202212 202112 % Var 202203 202103 % Var
Sales 7289.40 5332.70 36.69 21850.30 16063.00 36.03 21898.76 18919.95 15.74
Other Income 31.10 43.20 -28.01 53.40 367.60 -85.47 386.14 1118.89 -65.49
PBIDT 1726.00 1186.60 45.46 5086.00 4240.90 19.93 5475.24 6682.54 -18.07
Interest 86.50 13.00 565.38 220.40 33.70 554.01 49.49 71.92 -31.19
PBDT 1639.50 1173.60 39.70 4865.60 4207.20 15.65 5425.75 6610.62 -17.92
Depreciation 280.40 166.20 68.71 814.40 495.00 64.53 712.82 673.55 5.83
PBT 1359.10 1007.40 34.91 4051.20 3712.20 9.13 4712.93 5937.07 -20.62
TAX 347.00 261.60 32.65 1049.00 929.30 12.88 1102.91 1466.23 -24.78
Deferred Tax 210.50 -3.40 -6291.18 439.00 14.30 2969.93 -122.09 91.23 -233.83
PAT 1012.10 745.80 35.71 3002.20 2782.90 7.88 3610.02 4470.84 -19.25
Equity 154.70 154.60 0.06 154.70 154.60 0.06 154.56 154.56 0.00
PBIDTM(%) 23.68 22.25 6.41 23.28 26.40 -11.84 25.00 35.32 -29.21

JB Chem & Pharma Share Price

1978.00 -20.65 (-1.03%)
15-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1696.65
Dr. Reddys Lab 1218.30
Cipla 1226.65
Zydus Lifesciences 936.00
Lupin 2339.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×